Shares of Auris Medical Holding AG (NASDAQ:EARS) traded up 7.7% during mid-day trading on Friday . The company traded as high as $0.44 and last traded at $0.42. 1,071,609 shares were traded during trading, an increase of 122% from the average session volume of 482,252 shares. The stock had previously closed at $0.39.

Separately, Zacks Investment Research downgraded shares of Auris Medical from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th.

The company has a quick ratio of 1.86, a current ratio of 1.86 and a debt-to-equity ratio of -14.04.

A hedge fund recently bought a new stake in Auris Medical stock. Virtu KCG Holdings LLC bought a new stake in Auris Medical Holding AG (NASDAQ:EARS) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned about 0.32% of Auris Medical as of its most recent SEC filing. 26.46% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.